ISSN Approved Journal || eISSN: 2582-8185 || CODEN: IJSRO2 || Impact Factor 8.2 || Google Scholar and CrossRef Indexed
Fast Publication within 48 hours || Low Article Processing Charges || Peer Reviewed and Referred Journal || Free Certificate
Developing adaptive HIV treatment guidelines incorporating drug resistance surveillance and genotype-tailored therapies
1 Faculty of Pharmacy, OAU, Ile-Ife, Nigeria.
2 Department of Community Medicine, College of Medicine, Ladoke Akintola University of Technologies, Oyo State, Nigeria.
Review
International Journal of Science and Research Archive, 2021, 04(01), 373-392.
Article DOI: 10.30574/ijsra.2021.4.1.0172
Publication history:
Received on 02 October 2021; revised on 24 November 2021; accepted on 28 November 2021
Abstract:
The persistent global burden of HIV demands treatment frameworks that are both responsive and personalized, particularly in the face of rising drug resistance. Current antiretroviral therapy (ART) guidelines, while effective in many contexts, often lag behind the rapid emergence of HIV drug-resistant mutations and fail to account for inter-individual genetic variability that influences therapeutic response. This article examines the imperative to develop adaptive HIV treatment guidelines that integrate real-time drug resistance surveillance and genotype-tailored therapeutic strategies. Beginning from a global overview of ART evolution, the discussion narrows to highlight the challenges posed by acquired and transmitted resistance patterns, especially in resource-limited settings with high viral diversity and limited genomic monitoring infrastructure. We evaluate the benefits of incorporating routine resistance testing into national treatment protocols, including improved regimen durability, reduced treatment failure, and better alignment with WHO 95-95-95 targets. In parallel, we explore the potential of pharmacogenomic data such as host CYP450 polymorphisms and HLA profiles to optimize drug selection and dosing, minimizing toxicity and enhancing adherence. Using case studies from sub-Saharan Africa, Asia, and the U.S., we demonstrate the feasibility and clinical utility of integrating drug resistance data and host genomics into national HIV guidelines. The article concludes with a framework for adaptive policy design, leveraging artificial intelligence, electronic health records, and regional surveillance networks to support dynamic, patient-centric HIV treatment pathways. Such an approach represents a paradigm shift towards precision public health, where real-world data directly inform equitable, effective HIV care across diverse populations.
Keywords:
HIV Drug Resistance; Genotype-Guided Therapy; Adaptive Treatment Guidelines; Precision Public Health; Antiretroviral Therapy; Surveillance Systems
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
